Enhancement of Solubility and Bioavailability of β-Lapachone Using Cyclodextrin Inclusion Complexes

Pharmaceutical Research

Volumn 20, Issue 10, 2003, Pages 1626-1633

  Nasongkla, Norased ^a,b   Wiedmann, Andy F ^b   Bruening, Andrew ^c   Beman, Meghan ^c   Ray, Dale ^c   Bornmann, William G ^d   Boothman, David A ^c   Gao, Jinming ^b  

^a Case Western Reserve University   (United States)

^b Case Western Reserve University   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

lapachone; Bioavailability; Cyclodextrin; Inclusion complex; Solubility

Indexed keywords

ALPHA CYCLODEXTRIN; BETA CYCLODEXTRIN; BETA LAPACHONE; CYCLODEXTRIN; GAMMA CYCLODEXTRIN; HP BETA CYCLODEXTRIN; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL EXPERIMENT; AQUEOUS SOLUTION; ARTICLE; CELL ASSAY; CELL STRAIN MCF 7; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; FEMALE; FLUORESCENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LD 50; LETHALITY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

ADJUVANTS, PHARMACEUTIC; ALPHA-CYCLODEXTRINS; ANIMALS; BETA-CYCLODEXTRINS; BIOLOGICAL AVAILABILITY; CYCLODEXTRINS; GAMMA-CYCLODEXTRINS; HUMANS; INJECTIONS, INTRAPERITONEAL; LETHAL DOSE 50; MICE; MICE, INBRED C57BL; NAPHTHOQUINONES; SOLUBILITY; TUMOR CELLS, CULTURED;

EID: 0142074305     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026143519395     Document Type: Article

References (24)

1. A. Marin, A. Lopex de Cerain, E. Hamilton, A. D. Lewis, J. M. Martinez-Penuela, M. A. Idoate, and J. Bello. DT-diaphorase and cytochrome B5 reductase in human lung and breast tumors. Br. J. Cancer 76:923-929 (1997).
2. A. M. Malkinson, D. Siegel, G. L. Forrest, A. F. Gazdar, H. K. Oie, D. C. Chan, P. A. Bunn, M. Mabry, D. J. Dykes, S. D. Harrison, and D. Ross. Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin Cl. Cancer Res. 52:4752-1757 (1992).
3. A. M. Malkinson. Molecular comparison of human and mouse pulmonary adenocarcinomas. Exp. Lung Res. 24:541-555 (1998).
4. M. Belinsky and A. K. Jaiswal. NAD(P)H:quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues. Cancer Metastasis Rev. 12(2):103-117 (1993).
5. V. J. Stella and R. A. Rajewski. Cyclodextrins: Their future drug formulation and delivery. Pharm. Res. 14:556-567 (1997).
6. J. Szejtli. Introduction and general overview of cyclodextrin chemistry. Chem. Rev. 98:1743-1753 (1998).
7. T. Loftsson and M. E. Brewster. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization, J Pharm Sci. 85:1017-1025 (1996).
8. R. A. Rajewski and V. J. Stella. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J Pharm. Sci. 85:1142-1169 (1996).
9. T. Irie and K. Uekama. Pharmaceutical applications of cyclodextrins. 3. Toxicological issues and safety evaluation. J. Pharm. Sci. 86:147-162 (1997).
10. M. V. Rekharsky and Y. Inoue. Complexation thermodynamics of cyclodextrin. Chem. Rev. 98:1875-1917 (1998).
11. J. L. Lach and T. F. Chin. Interaction of pharmaceuticals with Schardinger dextrins III. J. Pharm. Sci. 53:69-73 (1964).
12. S. M. Planchon, S. Wuerzberger, B. Frydman, D. T. Witiak, P. Hutson, D. R. Church, G. Wilding, and D. A. Boothman. Beta-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response. Cancer Res. 55:3706-3711 (1995).
13. J. J. Pink, S. M. Planshon, C. Tagliarino, S. M. Wuerzberger-Davis, M. E. Varnes, D. Siegel, and D. A. Boothman. NAD(P)H:quinone oxidoreductase (NQO1) activity is the principal determinant of beta-lapachone cytoxicity. J. Biol. Chem. 275:5416-5424 (2000).
14. T. Higuchi and K. A. Connors. Phase solubility techniques. Adv. Anal. Chem. Instrum. 4:117-212 (1965).
15. A. Botsi, K. Yannakopoulou, B. Perly, and E. Hadjoudis. Positives or adverse effects of methylation on the inclusion behavior of cyclodextrins. A comparative NMR study using pheromone constituents of the olive fruit fly. J. Org. Chem. 60:4017-4023 (1995).
16. S. M. Wuerzberger, J. J. Pink, S. M. Planchon, K. L. Byers, W. G. Bornmann, and D. A. Boothman. Induction of apoptosis in MCF-7:WS8 breast cancer cells by beta-lapachone. Cancer Res. 58: 1876-1885 (1998).
17. C. Labarca and K. Paigen. A simple, rapid, and sensitive DNA assay procedure. Anal. Biochem. 102:344-352 (1980).
18. K. A. Connors. The stability of cyclodextrin complexes in solution. Chem. Rev. 97:1325-1357 (1997).
19. P. Adell, T. Parella, F. Sanchez-Ferrando, and A. Virgili. Clean selective spin-locking spectra using pulsed field gradients. J. Magn. Reson. 108:77-80 (1995).
20. Y. Ikeda, S. Motoune, T. Matsuoka, H. Arima, F. Hirayama, and K. Uekama. Inclusion complex formation of captopril with α- and β-cyclodextrins in aqueous solution: NMR spectroscopic and molecular dynamic studies. J. Pharm. Sci. 91:2390-2398 (2002).
21. V. Ramamurthy and D. F. Eaton. Photochemistry and photophysics within cyclodextrin cavities. Ace. Chem. Res. 21:300-306 (1988).
22. E. E. Sideris, G. N. Valsami, M. A. Koupparis, and P. E. Macheras. Determination of association constants in cyclodextrin/drug complexation using the Scatchard plot: application to β-cyclodextrin anilinonaphthalenesulfonates. Pharm. Res. 9:1568-1574 (1992).
23. C. Tagliarino, J. J. Pink, G. R. Dubyak, A. L. Nieminen, and D. A. Boothman. Calcium is a key signaling molecule in beta-lapachone-mediated cell death. J. Biol Chem. 276:19150-19159 (2001).
24. C. J. Li, Y. Z. Li, A. V. Pinto, and A. B, Pardee. Potent inhibition of tumor survival in vivo by beta-lapachone plus taxol: combining drugs imposes different artificial checkpoints. Proc. Natl. Acad. Sci. USA 96:13369-13374 (1999).